Aim Prophylactic human papillomavirus (HPV) vaccines are highly effective at preventing
pre–cancerous cervical lesions when given in a three–dose schedule. Some post–hoc trial …

Background Human papillomavirus (HPV) vaccination is a major strategy for preventing
cervical and other ano-genital cancers. Worldwide HPV vaccination introduction and …

Background Optimised two-dose human papillomavirus (HPV) vaccine schedules are now
endorsed for young adolescents by the World Health Organization. Limited data are …

Publicly funded administration of the quadrivalent HPV (qHPV) vaccine in school-aged girls
was implemented for all Canadian provinces and territories between 2007 and 2009 …

Background The efficacy and effectiveness of the quadrivalent human papillomavirus (HPV)
vaccine in preventing high-grade cervical lesions have been shown. However, data to …

Background Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause
approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate …

Objectives To determine the effect of human papillomavirus (HPV) quadrivalent vaccine on
the risk of developing subsequent disease after an excisional procedure for cervical …

Objective To assess the potential epidemiological and economic impact of a prophylactic
quadrivalent human papillomavirus (HPV)(6/11/16/18) vaccine for preventing cervical …

Background We assessed the cost-effectiveness of adding a quadrivalent (6/11/16/18)
human papillomavirus (HPV) vaccine to the current screening programme in the UK …

Background The long-term effectiveness of the quadrivalent human papillomavirus (qHPV)
vaccine was assessed by monitoring the combined incidence of cervical intraepithelial …